"We are pleased to be able to move our clinical program for Covaxin forward, which we hope will bring us closer to offering an alternative Covid-19 vaccine," Ocugen CEO Shankar Musunuri said in a statement.from Industry-Economic Times
Read The Rest:economictimes...
